Monday, December 23, 2024
Facebook Linkedin Twitter
HomeTagsRegeneRx Biopharmaceuticals

RegeneRx Biopharmaceuticals

Biotechnology

Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy

PR Newswire -
RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair, and regeneration, is reporting a new scientific publication describing the safety...
Biotechnology

RegeneRx Partner Signs LOI with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic Keratitis

PR Newswire -
RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair, and regeneration, is reporting today that its U.S. joint venture (JV)...
Biotechnology

RegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259

PR Newswire -
RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair, and regeneration, is reporting that its U.S. joint venture (JV) partner...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics

Load more
ReadMagazine © | All rights reserved |Contact Us | Privacy Policy| Become A Guest Writer | Advertise with Us